Understanding the Pharmacokinetics of Common Psychiatric Medications
Psychiatric prescribing in Australia has grown steadily over the past decade, with more than 16 million mental health-related prescriptions subsidised through the Pharmaceutical Benefits Scheme each year. For community pharmacists in Bondi Junction and Brisbane alike, dispensing these medicines safely requires more than a quick check for interactions. A working grasp of pharmacokinetics helps explain why some patients respond briskly to a starting dose, while others appear resistant or unusually sensitive.
Pharmacokinetics describes what the body does to a drug across four phases: absorption, distribution, metabolism and excretion. Psychiatric medications are particularly interesting because many have narrow therapeutic windows, long half-lives, and metabolic pathways vulnerable to drug-drug interactions. Knowing the time course of these agents supports better counselling, more accurate switching strategies, and fewer adverse events.
In everyday practice, the Therapeutic Goods Administration, the Pharmaceutical Society of Australia and resources such as the Australian Medicines Handbook help pharmacists stay current, but day-to-day decisions still rest on understanding how a given antidepressant or antipsychotic actually behaves once inside a patient. The principles below outline that behaviour for the most commonly dispensed classes.
The ADME Process in Psychiatric Drug Handling
Most oral psychiatric medications are absorbed through the small intestine and undergo first-pass metabolism in the liver before reaching systemic circulation. Bioavailability varies widely: many antidepressants and antipsychotics retain 60 to 90 percent of an oral dose, while others lose a substantial fraction to first-pass loss. Lipophilicity drives distribution, and nearly all centrally acting psychotropes cross the blood-brain barrier readily, although the P-glycoprotein efflux pump limits entry for several SSRIs and atypical agents.
Plasma protein binding is another variable to consider. Most psychotropes are highly protein bound and prone to displacement interactions in patients with low albumin. The CYP enzymes 2D6, 3A4, 2C19 and 1A2 handle the metabolism of the great majority of these drugs, and genetic polymorphisms in CYP2D6, present in roughly 5-10 percent of Australians of European descent, can convert a standard dose of codeine, tramadol or certain antidepressants into a clinical disappointment or a toxicity risk. Renal excretion completes the picture for drugs such as lithium, gabapentin and pregabalin, where kidney function is the dominant determinant of clearance.
SSRIs and Their Distinct Pharmacokinetic Footprints
Selective serotonin reuptake inhibitors are the workhorses of Australian primary care mental health, with citalopram, escitalopram, sertraline, fluoxetine and paroxetine among the most frequently prescribed. Each behaves quite differently once absorbed. Fluoxetine has a parent half-life of one to three days, but its active metabolite norfluoxetine lingers for up to sixteen days, giving it an extraordinarily long washout period when switching to a monoamine oxidase inhibitor.
Paroxetine is a potent CYP2D6 substrate and inhibitor, which can complicate co-prescribing with tamoxifen, codeine or metoprolol. Sertraline is metabolised primarily by CYP2C19, with CYP2D6 contributing at concentrations above the usual dose range. Citalopram carries a dose-dependent risk of QT prolongation, a concern now flagged in the product information and reflected in PBS listings that cap doses in older adults. Escitalopram, the S-enantiomer, has a cleaner cardiac profile but similar CYP2C19 dependence. The pharmacokinetic contrast between these SSRIs helps explain why moving between agents is rarely straightforward and why a four to five-week washout is recommended when transitioning from fluoxetine to a monoamine oxidase inhibitor.
SNRIs and Dual Reuptake Pharmacokinetics
The serotonin-noradrenaline reuptake inhibitors include venlafaxine, desvenlafaxine and duloxetine, and they share core pharmacokinetic features while differing in important ways. Venlafaxine has a parent half-life of roughly five hours, but its active metabolite O-desmethylvenlafaxine extends the clinical effect to about eleven hours and is the dominant species at steady state. CYP2D6 converts venlafaxine to this metabolite, so poor metabolisers receive less of the noradrenergic component and may experience a different therapeutic response.
Duloxetine relies heavily on CYP1A2 and CYP2D6 for clearance. The clinical relevance shows up when patients start or stop smoking: tobacco smoking induces CYP1A2, which can lower duloxetine concentrations by a third, sometimes prompting dose adjustments. Inflammation triggered by viral infections, including reactivation of herpesviruses discussed in resources on the herpes life cycle, can further alter CYP activity during acute illness. Desvenlafaxine bypasses CYP2D6 for its primary metabolism, which makes its pharmacokinetics more predictable across CYP2D6 genotypes, an advantage when treating patients whose metaboliser status is unknown.
Mood Stabilisers With Narrow Therapeutic Windows
Lithium, sodium valproate and carbamazepine are the classic mood stabilisers, and pharmacokinetics drives their safety profile more than almost any other class. Lithium is not metabolised at all. Instead it is filtered unchanged through the kidneys, with a half-life of roughly eighteen to thirty-six hours. Anything that reduces glomerular filtration or alters sodium handling, including dehydration, NSAIDs, thiazide diuretics or even a Perth heatwave, can push serum lithium into the toxic range. Regular therapeutic drug monitoring is therefore essential, and Australian guidelines recommend serum levels twelve hours post-dose every three to six months once stable.
Valproate is hepatically metabolised through glucuronidation and beta-oxidation, but it is also a CYP inhibitor and is heavily protein bound. Its half-life of nine to sixteen hours can extend considerably in patients with liver impairment. Carbamazepine is unusual because it induces its own metabolism: CYP3A4 activity increases over the first two to four weeks of therapy, shortening the half-life from about thirty-five hours at initiation to roughly twelve hours at maintenance. Autoinduction means dose adjustments are the norm, not the exception.
| Medication | Half-life (hours) | Primary metabolism | Active metabolite | Notable clinical concern |
|---|---|---|---|---|
| Fluoxetine | 24-72 (norfluoxetine up to 384) | CYP2D6 (inhibitor) | Norfluoxetine | Long washout, CYP2D6 inhibition |
| Sertraline | 26 | CYP2C19 | N-desmethylsertraline (weak) | Dose-dependent CYP2D6 inhibition |
| Paroxetine | 18-24 | CYP2D6 (substrate and inhibitor) | None significant | Withdrawal syndrome on cessation |
| Venlafaxine | 5 (ODV 11) | CYP2D6 | O-desmethylvenlafaxine | CYP2D6 genotype effects |
| Lithium | 18-36 | None, renal excretion | None | Narrow therapeutic index |
| Valproate | 9-16 | Hepatic, glucuronidation | None | Hepatotoxicity, teratogenicity |
Antipsychotics: From First-Generation to Long-Acting Injectables
Typical antipsychotics such as haloperidol and fluphenazine are heavily metabolised by CYP2D6 and CYP3A4. The atypical agents have expanded the picture considerably. Risperidone is converted to 9-hydroxyrisperidone, both of which are pharmacologically active, giving risperidone an effective half-life closer to twenty hours when both species are considered. Olanzapine is primarily cleared by CYP1A2, which means smokers in Sydney or Adelaide can require higher doses than non-smokers to achieve comparable plasma levels, while concurrent CYP1A2 inhibitors such as ciprofloxacin can elevate olanzapine concentrations.
Quetiapine has a short parent half-life of around six hours but is formulated to sustain therapeutic effect, often as a modified-release preparation. Aripiprazole and its long-acting intramuscular forms rely on CYP2D6 and CYP3A4, and the monthly aripiprazole monohydrate or aripiprazole lauroxil preparations offer very different pharmacokinetic profiles from the oral preparation, reaching peak levels several weeks after injection. Long-acting injectables are particularly relevant for community pharmacists in regional Queensland and Tasmania who monitor adherence in patients with schizophrenia or bipolar disorder, and the broader international conversation around pharmacy benefit manager impacts on independent pharmacies highlights access challenges familiar to dispensing pharmacists in many settings.
Benzodiazepines, Z-Drugs and Accumulation Risks
Benzodiazepines are absorbed rapidly and distributed widely because of their high lipophilicity. Diazepam demonstrates this clearly: a fast onset of anxiolytic effect, followed by redistribution into fat stores and a parent half-life of twenty to one hundred hours depending on age and liver function. Its active metabolites, including desmethyldiazepam, extend the clinical effect further, which is why diazepam accumulates in older patients and is best avoided in falls-related presentations.
Oxazepam, lorazepam and temazepam are metabolised only by glucuronidation and bypass phase I CYP metabolism, making them safer choices when liver function is impaired. Zopiclone and zolpidem are similarly short-acting but carry their own concerns: complex sleep-related behaviours, next-day sedation, and dependence with prolonged use. Pharmacokinetics also explains why benzodiazepines and Z-drugs should not be stopped abruptly after more than a few weeks of continuous use; rebound insomnia and, with short-acting agents, even seizure risk can follow sudden withdrawal.
Therapeutic Drug Monitoring in Australian Practice
Therapeutic drug monitoring is the practical application of pharmacokinetic knowledge, allowing dose individualisation when clinical response or toxicity suggests plasma concentrations are outside the usual range. Lithium, valproate and carbamazepine are the clear indications in psychiatric practice, but tricyclic antidepressants and clozapine also have well-defined therapeutic ranges where monitoring adds value. Clozapine, in particular, requires plasma level assessment if adherence is uncertain or if a patient begins smoking, develops an infection or starts a CYP1A2 inhibitor.
Pharmacists should also remember that pharmacokinetics can shift with acute illness. Inflammatory cytokines released during infection can suppress CYP enzymes and raise plasma levels of several psychiatric drugs within hours. For pharmacists wanting to deepen their understanding, practical commentary from experienced clinicians offers ongoing clinical context that complements formal guidelines and supports day-to-day decision making.
Pharmacists who understand absorption, distribution, metabolism and excretion can individualise therapy more confidently, counsel patients on what to expect when starting or switching agents, and identify interactions before they cause harm. The next time a patient in your pharmacy starts an antidepressant, an antipsychotic or a mood stabiliser, take a few minutes to think through its pharmacokinetic profile. You will be better placed to support safe, effective and personalised care, and your patients will benefit from the extra attention.